文献速递其他结缔组织病

征询专家先验意见以设计BARJDM幼年皮肌炎试验

Elicitation of expert prior opinion to design the BARJDM trial in juvenile dermatomyositis.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

通过贝叶斯先验征询会议,10名英国儿童风湿科顾问对BARJDM试验中患者12个月内停用糖皮质激素达到临床非活动性疾病概率给出先验意见。共识认为巴瑞替尼概率0.55、甲氨蝶呤0.23,巴瑞替尼不确定性更大。专家目前认为巴瑞替尼优于甲氨蝶呤但存在不确定性,BARJDM将整合随机试验数据与该先验意见推导后验分布。

要点

  • 10名英国儿童风湿科顾问参与先验征询,均具JDM专长并主持NHS活跃门诊。
  • 共识先验概率:12个月内停GC达临床非活动病,巴瑞替尼0.55、MTX 0.23。
  • 专家认为巴瑞替尼优于MTX但存在不确定性,BARJDM将整合试验数据与此先验。

核心结论

  • 专家目前认为巴瑞替尼治疗JDM优于甲氨蝶呤,但存在不确定性。
  • BARJDM将整合随机试验数据与该专家先验意见,推导巴瑞替尼相对甲氨蝶呤疗效的后验分布。

研究设计与样本

  • 采用先前描述的方法学模板召开贝叶斯先验征询会议。
  • 征询对象为10名英国儿童风湿科顾问(含1名青少年儿童风湿病学家),均具JDM专长并主持NHS活跃门诊。
  • 征询问题为BARJDM试验中患者12个月内停用糖皮质激素达到临床非活动性疾病的概率,比较甲氨蝶呤(标准治疗)与巴瑞替尼(JAK抑制剂),两臂GC方案相同。
  • 专家意见在展示并进一步讨论甲氨蝶呤或JAK抑制剂治疗JDM疗效的已发表汇总数据后进行了讨论和修正。

主要发现

  • 共识专家先验意见认为,12个月内停用GC达到临床非活动性疾病的最可能概率为巴瑞替尼0.55、甲氨蝶呤0.23。
  • 巴瑞替尼的不确定性程度大于甲氨蝶呤。

关键数值与推荐

  • 共识先验概率:12个月内停GC达临床非活动病,巴瑞替尼0.55 vs 甲氨蝶呤0.23。
  • 巴瑞替尼的不确定性程度大于甲氨蝶呤。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 专家先验意见存在不确定性,尤其巴瑞替尼的不确定性更大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To elicit and quantify expert opinion concerning the relative merits of two treatments for a rare inflammatory disease: JDM. The formal expression of expert opinion reported in this article will be used in a Bayesian analysis of a forthcoming randomized controlled trial known as BARJDM (baricitinib for JDM). METHODS: A Bayesian prior elicitation meeting was convened, following a previously described methodological template. Opinion was sought on the probability that a patient in the BARJDM trial would achieve clinically inactive disease, off glucocorticoids (GC) within a 12-month period with either MTX (standard of care); or baricitinib (a Janus kinase inhibitor, JAKi), with GC schedules identical in both arms of the trial. Experts' views were discussed and refined following presentation and further discussion of summated published data regarding efficacy of MTX or JAKi for JDM. RESULTS: Ten UK paediatric rheumatology consultants (including one adolescent paediatric rheumatologist) participated in the elicitation meeting. All had expertise in JDM, leading active National Health Service clinics for this disease. Consensus expert prior opinion was that the most likely probability of clinically inactive disease off GC within 12 months was 0.55 on baricitinib and 0.23 on MTX, with a greater degree of uncertainty for baricitinib. CONCLUSION: Experts currently think that baricitinib is superior to MTX for the treatment of JDM, although there is uncertainty around this. BARJDM will therefore integrate randomized trial data with this expert prior opinion to derive a posterior distribution for the relative efficacy of baricitinib compared with MTX.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Papadopoulou C, Martin N, Rafiq N, et al. Elicitation of expert prior opinion to design the BARJDM trial in juvenile dermatomyositis. Rheumatology (Oxford). 2024. PMID: 39073903. doi:10.1093/rheumatology/keae392

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。